Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advancements in Molecular Research of Prostate Cancer
share announcement

Advancements in Molecular Research of Prostate Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 3136

Special Issue Editor

Prof. Dr. Anait S. Levenson

E-Mail Website
Guest Editor
Department of Biomedical Sciences, College of Veterinary Medicine, Long Island University, Brookville, NY 11548, USA
Interests: prostate and breast cancers; molecular mechanisms of cancer progression; pre-clinical mouse models; targeted therapies; natural anticancer agents
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

We are delighted to announce the call for submissions to a Special Issue of Cancers focusing on the topic of "Advancements in Molecular Research of Prostate Cancer." Prostate cancer is a significant health concern worldwide, and understanding its molecular aspects is crucial for improved diagnosis, treatment, and patient outcomes.

This Special Issue aims to provide a comprehensive overview of the latest advancements in molecular research related to prostate cancer. We invite the submission of original research articles and reviews that cover various aspects of prostate cancer molecular biology, including but not limited to the following:

  • Genetic and epigenetic alterations in prostate cancer development and progression.
  • Identification and characterization of prostate cancer biomarkers for early detection and prognosis.
  • Molecular mechanisms underlying therapeutic resistance in prostate cancer.
  • Novel molecular targets and therapeutic strategies for prostate cancer treatment.
  • Genomic and proteomic profiling of prostate cancer to unravel its heterogeneity.
  • Modeling different stages of prostate cancer in genetically engineered mouse models.
  • Identification and characterization of novel molecular targets in prostate cancer.
  • Development and evaluation of targeted therapies for prostate cancer (pre-clinical and clinical studies).

All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to the field. We encourage contributions from researchers, clinicians, and experts in the field of prostate cancer research and oncology.

By consolidating the latest research findings and molecular insights, we aim to advance our understanding of prostate cancer and pave the way for personalized and effective therapeutic approaches. Your valuable contributions to this Special Issue will contribute significantly to the progress in prostate cancer research.

If you have any questions, require further information, or need any assistance, please do not hesitate to contact us. We are here to support and facilitate your participation in this Special Issue.

Thank you for your attention to this matter, and we eagerly anticipate receiving your valuable submissions.

Prof. Dr. Anait S. Levenson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • molecular targets
  • tumor heterogeneity
  • targeted interception and therapies
  • noninvasive biomarkers
  • precision oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 2118 KiB  
Article
The Role of Local Prostate and Metastasis-Directed Radiotherapy in the Treatment of Oligometastatic Prostate Cancer
by Seo Hee Choi, Seung-Hoon Beom, Young Deuk Choi, Won Sik Ham, Hyunho Han, Woong Kyu Han, Won Sik Jang, Seung Hwan Lee and Jaeho Cho
Cancers 2024, 16(18), 3159; https://doi.org/10.3390/cancers16183159 - 14 Sep 2024
Viewed by 1042
Abstract
Background/Objectives: Oligometastatic prostate cancer (OMPC) represents an early stage of metastatic disease characterized by a limited number of lesions. Recent advancements in imaging and treatment have revived interest in personalized therapies, including metastasis-directed radiotherapy (OMDRT) and primary prostate radiotherapy (PPR). This study evaluates [...] Read more.
Background/Objectives: Oligometastatic prostate cancer (OMPC) represents an early stage of metastatic disease characterized by a limited number of lesions. Recent advancements in imaging and treatment have revived interest in personalized therapies, including metastasis-directed radiotherapy (OMDRT) and primary prostate radiotherapy (PPR). This study evaluates the impact of OMDRT timing and the role of PPR on survival outcomes in OMPC patients; Methods: In this retrospective cohort study, 82 patients with OMPC who underwent OMDRT between 2010 and 2019 were analyzed. Patients were classified based on OMDRT timing (early vs. late) and disease type (synchronous vs. metachronous). Progression-free survival (PFS) and overall survival (OS) were the primary endpoints, assessed via Kaplan-Meier analysis and Cox proportional hazards models; Results: Among the patients, 36 (43.9%) had synchronous and 46 (56.1%) had metachronous OMD. With a median follow-up of 32 months, the 5-year PFS and OS rates were 77.5% and 88.5%, respectively. Early OMDRT significantly improved PFS (HR 0.461, 95% CI: 0.257–0.826, p = 0.009) and OS (HR 0.219, 95% CI: 0.080–0.603, p = 0.003). Subgroup analysis showed the most favorable outcomes for synchronous OMD patients receiving early OMDRT, with a median PFS of 22.2 months and a 5-year survival rate of 42.1%. The treatment of the primary prostate provided a survival benefit in the OS of synchronous OMD patients (5-year 83.1% vs. 50%, p = 0.025), and there was a further improvement in OS after PPR (5-year 87.7% vs. 50%, p = 0.015). Conclusions: Early OMDRT significantly enhances survival outcomes in OMPC, in both synchronous and metachronous cases. The integration of PPR can further improve results, emphasizing the importance of early intervention and personalized treatment strategies. To more definitively clarify our findings across various clinical situations, further studies with larger cohorts or prospective designs are necessary. Full article
(This article belongs to the Special Issue Advancements in Molecular Research of Prostate Cancer)
►▼ Show Figures

Figure 1

12 pages, 1472 KiB  
Article
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
by Enrique Perez-Navarro, Vincenza Conteduca, Juan M. Funes, Jose I. Dominguez, Miguel Martin-Serrano, Paolo Cremaschi, Maria Piedad Fernandez-Perez, Teresa Alonso Gordoa, Albert Font, Sergio Vázquez-Estévez, Aránzazu González-del-Alba, Daniel Wetterskog, Begona Mellado, Ovidio Fernandez-Calvo, María José Méndez-Vidal, Miguel Angel Climent, Ignacio Duran, Enrique Gallardo, Angel Rodriguez Sanchez, Carmen Santander, Maria Isabel Sáez, Javier Puente, Julian Tudela, Cecilia Marinas, María Jose López-Andreo, Daniel Castellano, Gerhardt Attard, Enrique Grande, Antonio Rosino, Juan A. Botia, Jose Palma-Mendez, Ugo De Giorgi and Enrique Gonzalez-Billalabeitiaadd Show full author list remove Hide full author list
Cancers 2024, 16(14), 2535; https://doi.org/10.3390/cancers16142535 - 14 Jul 2024
Viewed by 1539
Abstract
The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as transcriptional profiling and immune cell ratios. We aimed to address the contribution of distinct whole blood immune cell components to the prognosis of these patients. [...] Read more.
The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as transcriptional profiling and immune cell ratios. We aimed to address the contribution of distinct whole blood immune cell components to the prognosis of these patients. This study analyzed pre-treatment blood samples from 152 chemotherapy-naive mCRPC patients participating in a phase 2 clinical trial (NCT02288936) and a validation cohort. We used CIBERSORT-X to quantify 22 immune cell types and assessed their prognostic significance using Kaplan–Meier and Cox regression analyses. Reduced CD8 T-cell proportions and elevated monocyte levels were substantially connected with a worse survival. High monocyte counts correlated with a median survival of 32.2 months versus 40.3 months for lower counts (HR: 1.96, 95% CI 1.11–3.45). Low CD8 T-cell levels were associated with a median survival of 31.8 months compared to 40.3 months for higher levels (HR: 1.97, 95% CI 1.11–3.5). These findings were consistent in both the trial and validation cohorts. Multivariate analysis further confirmed the independent prognostic value of CD8 T-cell counts. This study highlights the prognostic implications of specific blood immune cells, suggesting they could serve as biomarkers in mCRPC patient management and should be further explored in clinical trials. Full article
(This article belongs to the Special Issue Advancements in Molecular Research of Prostate Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop